References
- Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998;16:2780–2795.
- Johnson PW, Rohatiner AZ, Whelan JS, et al Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 1995;13:140–147.
- Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993;20:75–88.
- Montoto S, Davies AJ, Matthews J, et al Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol 2007;25:2426–2433.
- Rohatiner A, Radford J, Deakin D, et al A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma. Br J Cancer 2001;85:29–35.
- Hiddemann W, Buske C, Dreyling M, et al Treatment strategies in follicular lymphomas: current status and future perspectives. J Clin Oncol 2005;23:6394–6399.
- Swenson WT, Wooldridge JE, Lynch CF, Forman-Hoffman VL, Chrischilles E, Link BK. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 2005;23:5019–5026.
- Sacchi S, Pozzi S, Marcheselli L, et al Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients. Cancer 2007;109:2077–2082.
- Liu Q, Fayad L, Cabanillas F, et al Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol 2006;24:1582–1589.
- Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005;23:8447–8452.
- Tan D, Rosenberg SA, Levy R, et al Survival in follicular lymphoma: the Stanford experience, 1960–2003. Blood 2007;110:1005A (Abstract 3428).
- Sebban C, Brice P, Delarue R, et al Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. J Clin Oncol 2008;26:3614–3620.
- A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987–994.
- Solal-Celigny P, Roy P, Colombat P, et al Follicular lymphoma international prognostic index. Blood 2004;104:1258–1265.
- Cheson BD, Pfistner B, Juweid ME, et al Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
- Altman DG, De Stavola BL, Love SB, Stepniewska KA. Review of survival analyses published in cancer journals. Br J Cancer 1995;72:511–518.
- Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley & Sons; 1980.
- Horning SJ. Follicular lymphoma, survival, and rituximab: is it time to declare victory? J Clin Oncol 2008;26:4537–4538.